Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared on X:
“New in J Cancer Policy: lower-dose ICIs.
- Pembro 2, nivo 2, atezo 10 mg/kg
- Est. Medicare savings 2018–2021: nearly $1.44B
- Nivo $943.1M, pembro $382.2M, atezo $114.4M
What moves first: FDA, CMS or vials?”
Title: Dose Optimization of Immune Checkpoint Inhibitors: A Policy opportunity to reduce costs and improve access to immunotherapy in the United States
Authors: Sameer Deshmukh, Arthi Sridhar, Nilansh Kataria, Chelsee Jensen, Scott Soefjie, Krishna Sajeev, S.M. Qasim Hussaini, Daria Chelysheva, Aakash Desai
Read the full study here.
Other articles from Aakash Desai on OncoDaily.